These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19066329)

  • 41. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leukemia. Q&A highlights.
    Frame D; Sessions J; Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S22. PubMed ID: 18056929
    [No Abstract]   [Full Text] [Related]  

  • 43. New drugs: paliperidone, dasatinib, and decitabine.
    Hussar DA
    J Am Pharm Assoc (2003); 2007; 47(2):298-302. PubMed ID: 17510013
    [No Abstract]   [Full Text] [Related]  

  • 44. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
    Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph
    Ishiyama K; Kitawaki T; Sugimoto N; Sozu T; Anzai N; Okada M; Nohgawa M; Hatanaka K; Arima N; Ishikawa T; Tabata S; Onaka T; Oka S; Nakabo Y; Amakawa R; Matsui M; Moriguchi T; Takaori-Kondo A; Kadowaki N
    Leukemia; 2017 Jan; 31(1):203-212. PubMed ID: 27349810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
    Ritchie DS; McBean M; Westerman DA; Kovalenko S; Seymour JF; Dobrovic A
    Blood; 2008 Mar; 111(5):2896-8. PubMed ID: 18073350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Katagiri S; Ohyashiki K
    Stem Cells Dev; 2012 Nov; 21(16):2939-48. PubMed ID: 22642671
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
    Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
    Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
    Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
    Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
    Christiansson L; Söderlund S; Mangsbo S; Hjorth-Hansen H; Höglund M; Markevärn B; Richter J; Stenke L; Mustjoki S; Loskog A; Olsson-Strömberg U
    Mol Cancer Ther; 2015 May; 14(5):1181-91. PubMed ID: 25761894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2014; 201():27-65. PubMed ID: 24756784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 57. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
    Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
    Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes.
    Iriyama N; Hatta Y; Takei M
    Cancer Med; 2016 Nov; 5(11):3223-3234. PubMed ID: 27726309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
    Kreutzman A; Jaatinen T; Greco D; Vakkila E; Richter J; Ekblom M; Hjorth-Hansen H; Stenke L; Melo T; Paquette R; Seggewiss-Bernhardt R; Guerci-Bresler A; Talbot A; Cayuela JM; Mahon FX; Porkka K; Lipton J; Partanen J; Rousselot P; Mustjoki S
    Exp Hematol; 2012 Nov; 40(11):906-913.e1. PubMed ID: 22842045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.